KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020)

Historic Income from Non-Controlling Interests for BeOne Medicines (ONC) over the last 4 years, with Q4 2020 value amounting to $96000.0.

  • BeOne Medicines' Income from Non-Controlling Interests fell 4216.87% to $96000.0 in Q4 2020 from the same period last year, while for Sep 2021 it was $96000.0, marking a year-over-year increase of 10270.65%. This contributed to the annual value of -$3.6 million for FY2020, which is 8548.72% down from last year.
  • As of Q4 2020, BeOne Medicines' Income from Non-Controlling Interests stood at $96000.0, which was down 4216.87% from -$1.4 million recorded in Q3 2020.
  • BeOne Medicines' 5-year Income from Non-Controlling Interests high stood at $1.5 million for Q4 2018, and its period low was -$1.4 million during Q3 2020.
  • Its 4-year average for Income from Non-Controlling Interests is -$401666.7, with a median of -$429000.0 in 2019.
  • Over the last 5 years, BeOne Medicines' Income from Non-Controlling Interests had its largest YoY gain of 349302.33% in 2018, and its largest YoY loss of 51333.33% in 2018.
  • BeOne Medicines' Income from Non-Controlling Interests (Quarter) stood at $43000.0 in 2017, then skyrocketed by 3493.02% to $1.5 million in 2018, then plummeted by 89.26% to $166000.0 in 2019, then tumbled by 42.17% to $96000.0 in 2020.
  • Its Income from Non-Controlling Interests stands at $96000.0 for Q4 2020, versus -$1.4 million for Q3 2020 and -$1.1 million for Q2 2020.